Sanofi
Anti-CEACAM5 antibodies and uses thereof
Last updated:
Abstract:
Disclosed are antibodies which bind human and Macaca fascicularis CEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding the antibodies. Also disclosed are immunoconjugates comprising the antibodies conjugated or linked to a growth-inhibitory agent, and pharmaceutical compositions comprising the antibodies or immunoconjugates of the invention. The antibodies or immunoconjugates are used for the treatment of cancer or for diagnostic purposes.
Status:
Grant
Type:
Utility
Filling date:
3 Sep 2019
Issue date:
17 May 2022